Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Microbix Biosystems Inc T.MBX

Alternate Symbol(s):  MBXBF

Microbix Biosystems Inc. develops and commercializes biological and technological solutions for human health and wellbeing. It enables the commercialization of diagnostic assays by making a range of critical ingredients and devices for the global diagnostics industry, notably antigens for immunoassays and its laboratory quality assessment products (QAPs) that support clinical lab proficiency testing, enable assay development and validation, or help ensure the quality of clinical diagnostic workflows. Its segments include development, manufacturing and sales of products relating to the medical diagnostics industry, namely antigens as test ingredients, quality assessment products to help ensure the accuracy of test workflows and viral transport medium to enable collection of patient test samples and, and development and commercialization of novel and proprietary products or technologies, such as Kinlytic. Its Kinlytic urokinase is a biologic thrombolytic drug used to treat blood clots.


TSX:MBX - Post by User

Comment by Mbxwatcheron Mar 23, 2022 11:49am
160 Views
Post# 34537910

RE:RE:RE:RE:RE:KRC insight

RE:RE:RE:RE:RE:KRC insight Read the entire report.   Well documented and well thought out.

Here I will throw myself on the proverbial sword.:
I beilieve I stated on more than one occassion that I was afraid that the company was withholding this report because it was paid research and they did not have to publish it.   I was wrong on this point.
He deals extensively with the perception of MBX as a Covid play, and I think that is exactly what has occurred here.   He explains extensively why that perception is wrong, and states that it is oversold. Frankly I believe we all think it is way oversold.

Anyway those on the board can read it for themselves, but it is very comprehensive, and at least for tme its a confidence boost while we sit in the 50's"

My one takeaway from the report is regarding QAP's automation:  He states: this is not a case of build it and they will come, but more of a statement rather firmer like "If you build it we will give you the business"

We are building it:  He did state we are behind by a quarter, which will likely come out at the AGM, but overall very positive.

As always thanks to the steady hands on the board.   Great information sharing.
<< Previous
Bullboard Posts
Next >>